logo
Share SHARE
FONT-SIZE Plus   Neg

Mercury General Q1 Profit Rises - Quick Facts

Mercury General Corp. (MCY) reported that its first-quarter net income was $73.4 million or $1.34 per share up from $58.2 million or $1.06 per share for the same period in 2011.

Operating income was $39.1 million or $0.71 per share for the first quarter of 2012 compared to $39.6 million or $0.72 per share for the same period in 2011. Analysts polled by Thomson Reuters expected the company to report earnings of $0.68 per share for the quarter. Analysts' estimates typically exclude special items.

Net premiums written were $658.3 million in the first quarter of 2012, essentially the same as the corresponding period in 2011. Revenues for the quarter rose to $722.68 million from $705.54 million in the prior year quarter. Three analysts had consensus revenue estimate of $679.46 million for the quarter.

The company said that its board declared a quarterly dividend of $0.61 per share. The dividend is to be paid on June 28, 2012 to shareholders of record on June 14, 2012.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Almost 71 percent of Americans say they don't save enough for their retirement, while around 54 percent believe they will never pay off their debt fully, according to a new national survey. The latest survey, commissioned by Experian together with Get Rich Slowly and other top U.S. personal finance... The biotech space is not for the faint hearted, given the ebbs and flows in terms of the returns from investing in it. However, for one who perseveres and astutely devises strategies with full cognizance of key regulatory events coming up, the probability of drug candidates getting FDA's blessings and sympathy plays in the space, it provides a sea of opportunity and huge upside prospects. Alcobra Ltd.'s Investigational New Drug Applications for drug candidate MDX in Attention Deficit Hyperactivity Disorder and Fragile X Syndrome have been put on full clinical hold, following adverse neurological findings in a pre-clinical study.
comments powered by Disqus
RELATED NEWS
Trade MCY now with 
Follow RTT